Ieq Capital LLC bought a new stake in shares of DexCom, Inc. (NASDAQ:DXCM – Free Report) in the second quarter, according to its most recent Form 13F filing with the SEC. The fund bought 92,014 shares of the medical device company’s stock, valued at approximately $6,197,000.
Several other institutional investors and hedge funds have also recently bought and sold shares of DXCM. Geode Capital Management LLC boosted its holdings in shares of DexCom by 0.4% in the fourth quarter. Geode Capital Management LLC now owns 11,006,183 shares of the medical device company’s stock valued at $727,842,000 after acquiring an additional 42,411 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in shares of DexCom by 6.9% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 7,999,057 shares of the medical device company’s stock valued at $530,897,000 after acquiring an additional 516,526 shares during the period. Norges Bank bought a new stake in DexCom during the fourth quarter worth approximately $483,356,000. Invesco Ltd. lifted its position in DexCom by 14.8% in the fourth quarter. Invesco Ltd. now owns 5,315,367 shares of the medical device company’s stock worth $352,781,000 after purchasing an additional 686,228 shares during the period. Finally, CIBC Private Wealth Group LLC lifted its position in DexCom by 7.6% in the fourth quarter. CIBC Private Wealth Group LLC now owns 3,128,114 shares of the medical device company’s stock worth $207,613,000 after purchasing an additional 220,313 shares during the period. Institutional investors own 97.75% of the company’s stock.
DexCom Price Performance
Shares of NASDAQ:DXCM opened at $92.34 on Monday. DexCom, Inc. has a fifty-two week low of $54.11 and a fifty-two week high of $92.56. The business has a 50-day moving average of $77.49 and a two-hundred day moving average of $70.93. The stock has a market capitalization of $34.85 billion, a P/E ratio of 36.50, a P/E/G ratio of 1.56 and a beta of 1.41. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.73 and a quick ratio of 1.43.
Analysts Set New Price Targets
DXCM has been the subject of several research reports. William Blair raised DexCom to a “strong-buy” rating in a research note on Friday, May 15th. Benchmark boosted their price target on shares of DexCom from $77.00 to $82.00 and gave the stock a “buy” rating in a research report on Friday, July 31st. Robert W. Baird set a $105.00 price target on shares of DexCom in a report on Friday, July 31st. Barclays reissued an “underweight” rating and issued a $64.00 price target (down from $67.00) on shares of DexCom in a report on Monday, May 18th. Finally, Wells Fargo & Company lifted their price objective on shares of DexCom from $85.00 to $90.00 and gave the stock an “overweight” rating in a research note on Friday, July 31st. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $88.71.
Read Our Latest Report on DXCM
Insider Activity at DexCom
In other DexCom news, EVP Jon Coleman sold 4,911 shares of the business’s stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $74.13, for a total value of $364,052.43. Following the sale, the executive vice president owned 95,450 shares of the company’s stock, valued at $7,075,708.50. The trade was a 4.89% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kevin R. Sayer sold 26,756 shares of the company’s stock in a transaction dated Monday, July 20th. The shares were sold at an average price of $76.32, for a total transaction of $2,042,017.92. Following the completion of the sale, the insider directly owned 328,970 shares in the company, valued at approximately $25,106,990.40. The trade was a 7.52% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 73,035 shares of company stock valued at $5,446,673. Company insiders own 0.28% of the company’s stock.
About DexCom
DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.
Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.
Featured Articles
- Five stocks we like better than DexCom
- VIG, VYM, and VYMI: Which Vanguard Dividend ETF Is Right for You?
- 3 Closed-End Funds to Maximize Dividend Payments
- Rocket Lab’s Sell-Off Is Fading—Is It Finally Safe to Buy?
- $27 Billion in Buybacks: 3 Stocks Betting Their Strong Runs Aren’t Over
Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM – Free Report).
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.
